The implementation of the "two-invoice system" in the procurement of medicines in public medical institutions (for trial implementation), Article 2 of the "two-invoice system" refers to the fact that the drug manufacturer to the circulation enterprise to open an invoice, the circulation enterprise to the medical institutions to open an invoice. The two-invoice system" means that the drug manufacturer will issue an invoice to the distributing enterprise once, and the distributing enterprise will issue an invoice to the medical institution. Drug manufacturers or science, industry and trade integration of group-type enterprises set up only the sale of the enterprise (group) of wholly-owned or controlling commercial companies (the country is limited to one commercial company), the domestic general agent of foreign drugs (the country is limited to one domestic general agent) can be regarded as the production of enterprises.
Pharmaceutical distribution group-type enterprises within the wholly-owned (controlling) subsidiaries or wholly-owned (controlling) subsidiaries between the transfer of drugs may not be regarded as a one-vote, but at most allowed to issue an invoice. Drug production and distribution enterprises should be in accordance with the principles of fairness, legality and honesty and credit to reasonably determine the level of markup. Encourage public medical institutions and drug manufacturers to directly settle drug payments, drug manufacturers and distribution companies to settle distribution costs.